Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV
Jessica J. Wyse, Kathleen A. McGinnis, E. Jennifer Edelman, Adam J. Gordon, Ajay Manhapra, David A. Fiellin, Brent A. Moore, P. Todd Korthuis, Amy J. Kennedy, Benjamin J. Oldfield, Julie R. Gaither, Kirsha S. Gordon, Melissa Skanderson, Declan T. Barry, Kendall Bryant, Stephen Crystal, Amy C. Justice, Kevin L. Kraemer
09/08/2021
Abstract: Although opioid agonist therapy (OAT) is associated with positive health outcomes, including improved HIV management, long-term retention in OAT remains low among patients with opioid use disorder (OUD). Using data from the Veterans Aging Cohort Study (VACS), we identify variables independently associated with OAT retention overall and by HIV status…